What are the recommended dosing, monitoring, and contraindications for doxepin?

Doxepin: Dosing, Monitoring, and Contraindications

For insomnia, start doxepin at 3-6 mg at bedtime; for depression, start at 25-75 mg daily with gradual titration up to 150-300 mg as needed; avoid use in patients with glaucoma, urinary retention, or concurrent MAOI therapy.

Dosing Recommendations

For Insomnia (Low-Dose)

• Starting dose: 3-6 mg at bedtime 1, 2
• Maximum dose: 6 mg (no evidence that higher doses improve efficacy) 3, 4
• Elderly patients: Start at 3 mg 4
• Onset of action: Immediate (first night) with sustained effects 3, 4
• Duration: Approved for continuous use without short-term restriction 5

Low-dose doxepin (3-6 mg) significantly improves sleep maintenance and total sleep time but does not reduce sleep onset latency 3, 4. The 3 mg and 6 mg doses show equivalent efficacy, so starting at 3 mg is reasonable, particularly in older adults 4.

For Depression/Anxiety

• Starting dose: 25-75 mg daily 2
• Typical therapeutic range: 75-150 mg/day 2
• Maximum dose: 300 mg/day (rarely needed; doses above 300 mg provide minimal additional benefit) 2
• Elderly/debilitated patients: Start at 10-25 mg 6
• Dosing schedule: Can be given once daily at bedtime (maximum 150 mg) or divided doses 2
• Time to effect: Anti-anxiety effects appear before antidepressant effects; optimal antidepressant response may take 2-3 weeks 2

Titration strategy: Increase by 25 mg every 5-7 days as tolerated until therapeutic benefit or dose-limiting side effects occur 6. After 9 months of treatment, consider dose reduction to reassess need for continued medication 6.

For Chronic Urticaria (Off-Label)

• Dose: 25-50 mg daily 7
• Significantly reduces lesions, pruritus, and need for concomitant antihistamines 7

Monitoring Parameters

Clinical Monitoring

• Suicidality risk: Close monitoring during initial weeks and after dose changes, especially in patients <24 years old 2
• Anticholinergic effects: Dry mouth, constipation, urinary retention, blurred vision 2
• Cardiovascular effects: Blood pressure, heart rate (particularly in elderly) 2
• CNS effects: Drowsiness, confusion, falls risk in elderly 2
• Weight changes: Monitor for weight gain 2

Laboratory Monitoring

No routine laboratory monitoring is required for low-dose doxepin used for insomnia 1, 3.

For higher doses (depression/anxiety):

• Baseline: Consider ECG in patients with cardiac disease or risk factors 2
• Periodic monitoring: If specific side effects emerge (e.g., liver enzymes if hepatotoxicity suspected, CBC if blood dyscrasia suspected) 8
• Blood level monitoring (optional): Therapeutic range is controversial; proposed working range of 50-250 ng/mL (parent + metabolite) 9. However, only 9% of patients achieve the traditionally cited 150-250 ng/mL range at standard doses 9. Blood level monitoring is most useful when patients fail to respond to typical doses, allowing safe dose escalation 10.

Cardiac Considerations

Doxepin does not prolong QTc interval at doses up to 50 mg 11. Unlike citalopram, there is no specific QT prolongation warning for doxepin 11.

Contraindications

Absolute Contraindications

• Hypersensitivity to doxepin or other dibenzoxepines 2
• Narrow-angle glaucoma or untreated anatomically narrow angles (risk of angle-closure attack) 2
• Urinary retention 2
• Concurrent MAOI use or within 14 days of MAOI discontinuation (risk of serotonin syndrome) 12, 2

Relative Contraindications/Cautions

Cardiovascular disease:

• Use with caution in patients with cardiac conduction abnormalities, arrhythmias, or recent MI 2
• Monitor blood pressure (hypotension/hypertension possible) 2

Respiratory conditions:

• Caution in asthma, COPD, sleep apnea (sedation may worsen respiratory compromise) 5, 2

Hepatic impairment:

• Reduce dose; maximum 2 mg for insomnia in severe hepatic impairment 5

Elderly patients:

• Start at lowest dose due to increased risk of falls, confusion, anticholinergic effects 2
• Increased sensitivity to sedation and orthostatic hypotension 2

Pregnancy/lactation:

• Not recommended; apnea and drowsiness reported in nursing infant 2

Bipolar disorder:

• Screen for bipolar disorder before initiating; may precipitate manic episode 2

Children <12 years:

• Not recommended; safety not established 2

Important Drug Interactions

• MAOIs: Absolutely contraindicated (serotonin syndrome risk) 12, 2
• Other serotonergic drugs: Caution with SSRIs, SNRIs, tramadol, triptans (serotonin syndrome risk) 12
• CNS depressants: Additive sedation with alcohol, benzodiazepines, opioids 5, 2
• Anticholinergic drugs: Additive anticholinergic effects 2
• CYP2D6 substrates: Doxepin may inhibit metabolism of drugs metabolized by CYP2D6 12

Common Pitfalls

Dosing confusion: The 3-6 mg insomnia dose is vastly different from the 75-300 mg depression dose. Prescribing depression doses for insomnia causes excessive sedation and anticholinergic effects 1, 3.

Rebound insomnia: Some patients experience rebound insomnia upon discontinuation, even with low doses 8. Taper gradually over 10-14 days rather than abrupt cessation 6.

Misattributing treatment failure: Patients not responding to standard depression doses may have subtherapeutic blood levels due to genetic polymorphisms or drug interactions 10, 9. Consider blood level monitoring before declaring treatment failure 10.

Anticholinergic burden in elderly: Doxepin has significant anticholinergic activity compared to alternatives like trazodone 5. In elderly patients with multiple anticholinergic medications, consider alternatives.

Next-day sedation: Low-dose doxepin (3-6 mg) does not cause next-day residual sedation 3, 4, unlike higher doses used for depression.